BioNTech SE

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -3.84%326.540.0%$4164.11m
NVAXNovavax, Inc. -3.05%134.5679.4%$783.60m
BNTXBioNTech SE -2.80%278.340.0%$777.03m
AMGNAmgen, Inc. 0.12%209.241.4%$532.78m
REGNRegeneron Pharmaceuticals, Inc. 0.53%572.362.7%$454.63m
SNSSSunesis Pharmaceuticals, Inc. -0.33%6.090.7%$425.71m
CCXIChemoCentryx, Inc. -1.26%34.572.9%$397.56m
GILDGilead Sciences, Inc. 0.37%67.241.0%$393.07m
ILMNIllumina, Inc. -0.59%409.153.3%$356.80m
XLRNAcceleron Pharma, Inc. 0.12%173.955.3%$346.86m
VRTXVertex Pharmaceuticals, Inc. -1.91%183.521.9%$275.34m
BIIBBiogen, Inc. -2.00%264.801.7%$255.53m
OCGNOcugen, Inc. -1.66%8.320.0%$187.94m
XENEXenon Pharmaceuticals, Inc. 0.75%30.860.4%$166.06m
CRSPCRISPR Therapeutics AG -1.55%95.560.6%$159.15m

Company Profile

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.